Aarti Drugs Limited has scheduled its Quarterly Earnings Conference Call for investors and analysts on Monday, August 3, 2026, at 11:00 AM IST. The call has been convened to discuss the company's financial performance for the quarter ended June 30, 2026 (Q1 FY27). The intimation was filed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and signed by Company Secretary & Compliance Officer Rushikesh Vivek Deole.

Conference Call Details

The earnings call will be accessible to participants across multiple geographies. The scheduled timings across key time zones are as follows:

Key Participants

The following senior representatives of Aarti Drugs are scheduled to participate in the conference call:

• Mr. Harshit Savla — Joint Managing Director
• Mr. Harit Shah — Whole Time Director
• Mr. Adhish Patil — Chief Finance Officer & Chief Operating Officer
• Mr. Vishwa Savla — Managing Director, Pinnacle Life Science Private Limited

Dial-In Information

Investors and analysts wishing to join the call may use the following country-specific dial-in numbers:

For RSVP and further assistance, participants may contact Strategic Growth Advisors Pvt. Ltd. — Mr. Deven Dhruva at +91 98333 73300 or Ms. Krisha Shrimankar at +91 87797 99281.

Aarti Drugs has been directed by the Gujarat Pollution Control Board (GPCB) to shut down its Amines plant, marking a significant regulatory action against the pharmaceutical company. The order reflects the GPCB's mandate to enforce environmental compliance standards across industrial operations in the state.

Regulatory Action by GPCB

The Gujarat Pollution Control Board issued the shutdown directive specifically targeting Aarti Drugs' Amines plant. The GPCB is the statutory authority responsible for monitoring and regulating pollution-related activities of industries operating within Gujarat, and such orders are issued when units are found to be in contravention of prescribed environmental norms.

Impact on Operations

The shutdown order pertains to the Amines plant of Aarti Drugs, which forms a part of the company's manufacturing operations. Compliance with such regulatory directives is mandatory, and the company will be required to address the concerns raised by the GPCB before resuming operations at the affected facility.